The CF STORM Trial: A trial investigating the effects of stopping nebulised therapies for people on Kaftrio
Details
- Therapeutic approach
- Other
- Trial status
- Recruitment complete Participating Centres
- Trials Tracker ID
- TT005796
- Last updated
- 12/05/2022
CF STORM: A trial to assess change in respiratory function for people with cystic fibrosis on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies
Study detailsFor people with cystic fibrosis (pwCF), how to reduce treatment burden has been identified as the top priority research question. Daily nebulised treatments were identified by pwCF as burdensome.
The CF STORM trial will recruit pwCF age 6 years and above that have been established on Kaftrio™ therapy. They will have an equal chance of being allocated to either stop or continue their daily nebulised muco-active therapies (dornase alfa, hypertonic saline or both).
The trial is designed to provide confidence that stopping these nebulisers does not result in a significant decline in lung function over 12 months.
The trial will not involve extra visits outside of normal clinical care.
Find out more on the CF STORM website.
Read our blog about CF STORM.
- Phase
- Phase 4
- Recruitment target
- 764
- CF sponsor
- Alder Hey - Liverpool
- CF sponsor type
- Academic
Who can take part?
- Age range
- 6+
- Including people
1) Established on Kaftrio™ therapy for more than 3 months
2) FEV1 > 40 percent predicted
3) Established on daily muco-active therapies (dornase alfa (Pulmozyme™), hypertonic saline or both) for more than 3 months
4) 6 years and older
Get in touch